Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Autor: Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team

Publikováno v: Cancer Medicine, Vol 9, Iss 2, Pp 432-439 (2020)

Abstract Background Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidl

Externí odkaz: https://doaj.org/article/f888be4cb547443ca22958a679b90330

Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study

Autor: Christos Chouaïd, Nicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, LaurenceBigay Game, AnneMarie Chiappa, Regine Lamy, Florian Guisier, Hervé Le Caer, Gilles Robinet, Acya Bizieux, null GFPC

Publikováno v: Journal of cancer research and therapeutics. 18

Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers.All patients consecu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c56c977c695e17b3e62de096ad40ef53
https://pubmed.ncbi.nlm.nih.gov/36510958

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Autor: Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch, Judith Balmaña, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy, Constanta Timcheva, Antoaneta Tomova, Andrea Eisen, Karen Gelmon, Julie Lemieux, Fernando Bazan, Hugues Bourgeois, Camille Chakiba, Mohamad Chehimi, Florence Dalenc, Thibault De La Motte Rouge, Jean-Sébastien Frenel, Anthony Gonçalves, Anne Claire Hardy-Bessard, Regine Lamy, Christelle Levy, Alain Lortholary, Audrey Mailliez, Jacques Medioni, Anne Patsouris, Dominique Spaeth, Luis Teixeira, Isabelle Tennevet, Cristian Villanueva, Benoit You, Johannes Ettl, Bernd Gerber, Oliver Hoffmann, Tjoung-Won Park-Simon, Mattea Reinisch, Joke Tio, Pauline Wimberger, Katalin Boer, Alberto Ballestrero, Giampaolo Bianchini, Laura Biganzoli, Roberto Bordonaro, Francesco Cognetti, Michelino De Laurentiis, Sabino De Placido, Valentina Guarneri, Filippo Montemurro, Giuseppe Naso, Armando Santoro, Claudio Zamagni, Seung-Jin Kim, Seigo Nakamura, Yee Soo Chae, Eun Kyung Cho, Kim Jee Hyun, Seock-Ah Im, Keun Seok Lee, Yeon Hee Park, Joo Hyuk Sohn, Tomasz Byrski, Tomasz Huzarski, Bozena Kukielka-Budny, Zbigniew Nowecki, Renata Szoszkiewicz, Rafal Tarnawski, Viktoria Dvornichenko, Fedor Moiseenko, Guzel Mukhametshina, Elena Poddubskaya, Ekaterina Popova, Anna Tarasova, Anna Vats, Bárbara Adamo, Raquel Andrés Conejero, Antonio Antón Torres, Judith Balmaña Gelpi, Nieves Díaz Fernández, Alejandro Falcón González, Juan Garcia, Isabel Lorenzo-Lorenzo, Fernando Moreno Antón, Marta Santisteban, Agostina Stradella, Chiun-Sheng Huang, Sercan Aksoy, Cagatay Arslan, Mehmet Artac, Adnan Aydiner, Ozgur Ozyilkan, Emel Sezer, Anne Armstrong, Sophie Barrett, Annabel Borley, Zoe Kemp, Caroline Michie, Mukesh Mukesh, Timothy Perren, Angela Swampillai, Tammy Young

Publikováno v: European journal of cancer (Oxford, England : 1990). 152

Background In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-nega

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf39309b7bb719fd0c3675e31c646e0c
https://pubmed.ncbi.nlm.nih.gov/34087573

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

Autor: Karim Amrane, Margaux Geier, Romain Corre, Hervé Léna, Guillaume Léveiller, Florence Gadby, Régine Lamy, Jean‐Louis Bizec, Eric Goarant, Gilles Robinet, Sylvie Gouva, Gilles Quere, Ronan Abgral, Ulrike Schick, Cyril Bernier, Christos Chouaid, Renaud Descourt

Publikováno v: Cancer Medicine, Vol 9, Iss 7, Pp 2309-2316 (2020)

Abstract Background The KEYNOTE‐024 trial demonstrated that pembrolizumab, a PD‐1 inhibitor, significantly improves progression‐free survival (PFS) and overall survival (OS) in selected patients with previously untreated advanced non–small ce

Externí odkaz: https://doaj.org/article/c98d4e070de24144a3c13472f5f9c857

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 'EPNEC' study

Autor: Dominique Arpin, Marie-Christine Charpentier, Marie Bernardi, Isabelle Monnet, Aurelie Boni, Emmanuel Watkin, Isabelle Goubin-Versini, Régine Lamy, Laurence Gérinière, Margaux Geier, Fabien Forest, Radj Gervais, Anne Madrosyk, Florian Guisier, Cécile Serrand, Chrystèle Locher, Chantal Decroisette, Pierre Fournel, Jean-Bernard Auliac, Thierry Jeanfaivre, Jacques Letreut, Hélène Doubre, Geraldine Francois, Nicolas Piton, Christos Chouaïd, Diane Damotte

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 12 (2020)

Background: Few data are available on programmed cell-death-protein-1–ligand-1 (PD-L1) expression on large-cell neuroendocrine carcinomas of the lung (LCNECs). We analyzed PD-L1 expression on tumor (TCs) and inflammatory cells (ICs) from LCNEC pati

Externí odkaz: https://doaj.org/article/38ff50573e604ef38fa38fe4c193a9ac